Key Details
- The company received an email from BSE Limited's Surveillance Team dated June 10, 2026, with reference number L/SURV/ONL/PV/SG/2026-2027/126
- The query sought clarification on significant increase in trading volume of the company's securities across exchanges in the recent past
- Company response states that all required disclosures have been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- The company confirms it has not withheld any material information or events that would have a bearing on price/volume behavior of the scrip
- No specific financial impact or quantitative volume data was disclosed in the response
Parties Involved
- BSE Limited (regulatory exchange)
- Solara Active Pharma Sciences Limited (responding company)
Financial Impact
No quantitative financial impact disclosed. The response is procedural in nature addressing regulatory compliance requirements.